INMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (29 4月 2024 @ 23:33):

Stats
本日の出来高	40 402.00
平均出来高	382 840
時価総額	1.42M
EPS	$0 ( 2024-02-16 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.560
ATR14	$0.00300 (1.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-14	Hull Andrew	Sell	42	Employee Stock Option (Expiration)
2024-03-04	Hsu Eric C	Sell	309	Employee Stock Option (Expiration)
2024-01-21	Mancini Alexandra Diane Janet	Sell	121	Employee Stock Option (Expiration)
2024-02-20	Jagpal Netta	Sell	50 000	Employee Stock Option (Right to Buy)
2024-02-21	Hull Andrew	Buy	37 500	Common Stock

INSIDER POWER
74.61
Last 93 transactions
Buy: 1 291 573 \| Sell: 391 310

ボリューム相関

長: -0.22 (neutral)

短: 0.01 (neutral)

Signal:(44.428) Neutral

InMed Pharmaceuticals 相関

10 最も正の相関
ZSAN	0.901
KBSF	0.889
BNOX	0.885
ARQQ	0.884
AYLA	0.884
VIH	0.884
LYRA	0.882
QLGN	0.881
LQDT	0.879
DWACU	0.87

10 最も負の相関
STAY	-0.89
AVGO	-0.884
TIPT	-0.883
BNIXU	-0.876
TVTY	-0.875
ARDX	-0.874
USLM	-0.872
LRFC	-0.869
LUNA	-0.864
PEBK	-0.862

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

InMed Pharmaceuticals 相関 - 通貨/商品

0.00
( neutral )

0.47
( neutral )

0.00
( neutral )

-0.09
( neutral )

InMed Pharmaceuticals 財務諸表

Annual	2023
収益:	$4.14M
総利益:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2023
収益:	$4.14M
総利益:	$1.40M (33.93 %)
EPS:	$-3.25

FY	2022
収益:	$1.09M
総利益:	$543 546 (49.89 %)
EPS:	$-41.74

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-38.00

Financial Reports:

No articles found.

InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.